Asthma-COPD overlap
Asthma-COPD overlap | |
---|---|
Synonyms | ACO |
Pronounce | N/A |
Specialty | N/A |
Symptoms | Shortness of breath, wheezing, cough, sputum production |
Complications | Exacerbations, respiratory failure, pulmonary hypertension |
Onset | Typically adulthood |
Duration | Chronic |
Types | N/A |
Causes | Combination of asthma and chronic obstructive pulmonary disease |
Risks | Smoking, air pollution, occupational exposure |
Diagnosis | Spirometry, clinical evaluation |
Differential diagnosis | Asthma, COPD, bronchiectasis |
Prevention | Smoking cessation, vaccination, avoiding triggers |
Treatment | Inhaled corticosteroids, bronchodilators, oxygen therapy |
Medication | Corticosteroids, beta-agonists, anticholinergics |
Prognosis | Variable, depends on management and comorbidities |
Frequency | Common in patients with features of both asthma and COPD |
Deaths | N/A |
Asthma-COPD Overlap (ACO) is a condition that combines features of both Asthma and Chronic Obstructive Pulmonary Disease (COPD), leading to a complex respiratory disorder. It is characterized by persistent airflow limitation with several features usually associated with asthma and several features usually associated with COPD. ACO is increasingly recognized in the clinical setting, underscoring the need for a tailored approach to diagnosis and management.
Definition
ACO is defined by the presence of increased variability of airflow in combination with an incompletely reversible airflow obstruction. This condition is identified in patients who exhibit characteristics of both asthma and COPD, a scenario that complicates management and treatment strategies. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) and the Global Initiative for Asthma (GINA) have provided guidelines to help in the identification and management of ACO.
Epidemiology
The prevalence of ACO varies widely, depending on the diagnostic criteria used. It is estimated that about 15-25% of individuals with COPD or asthma may have features of the overlap syndrome. ACO is more common in individuals over the age of 40 years, who have a history of smoking or exposure to biomass fuel.
Pathophysiology
The pathophysiological mechanisms underlying ACO involve aspects of both airway inflammation and remodeling seen in asthma, and the chronic obstructive changes associated with COPD. This includes chronic inflammation from various cells like neutrophils, eosinophils, and lymphocytes, along with structural changes in the airway walls and lung parenchyma.
Clinical Features
Patients with ACO may present with symptoms common to both asthma and COPD, including chronic cough, sputum production, wheezing, and shortness of breath. These symptoms are often more severe than in individuals with asthma or COPD alone and can lead to a higher frequency of exacerbations and a more rapid decline in lung function.
Diagnosis
Diagnosis of ACO requires a careful clinical assessment, including a detailed patient history and physical examination, spirometry with bronchodilator testing, and possibly other tests such as chest X-ray, high-resolution CT scan, and measurement of blood eosinophils. Identifying features of both asthma and COPD is key to diagnosing ACO.
Management
Management of ACO involves a combination of pharmacological and non-pharmacological treatments aimed at controlling symptoms, improving quality of life, and preventing exacerbations. Treatment may include the use of inhaled corticosteroids, long-acting beta-agonists, long-acting muscarinic antagonists, and short-acting bronchodilators. Smoking cessation, vaccination, pulmonary rehabilitation, and management of comorbidities are also important aspects of care.
Prognosis
The prognosis of ACO is generally considered to be worse than that of asthma or COPD alone due to the increased risk of exacerbations, hospitalizations, and mortality. However, with appropriate management, individuals with ACO can achieve a good quality of life and a level of symptom control.
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD